Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @MerrimackPharma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MerrimackPharma
-
We are taking a systematic approach to our preclinical development work. Learn more about our pipeline here: https://bit.ly/2p1NcPm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our pipeline is shaped by understanding cancer pathways, treatments designed with pharmacological properties to match disease need, and clinical strategies with clear rationale. https://bit.ly/2p1NcPm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
October is
#BreastCancerAwareness Month. At Merrimack, we stand with everyone who has been affected by this disease and we will continue to work to develop new treatments.#BCAMHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At Merrimack, innovation is at our core. Want to help us answer the tough questions? Explore our open positions and join our team today: https://bit.ly/2BS6JqN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Meet Daryl Drummond, Ph.D., our Head of Research. Daryl is a principal inventor for many of our nanotechnology-based candidates. https://bit.ly/2BUVOfS pic.twitter.com/AIcYvIdFv1
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced the receipt of a $5 million milestone payment from Shire. Read more in the full release:https://bit.ly/2NtzYXu
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our vision is to see a world where all cancer patients and their families can live fulfilling lives.pic.twitter.com/fgRfQ3xXwS
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In case you missed our paper in
@scisignal, we recently developed a multi-scale computational model that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate. Read more here:https://bit.ly/2xvwVmWHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced the completion of enrollment in our randomized Phase 2 clinical trial evaluating our lead investigational drug candidate, MM-121, in patients with heregulin positive non-small cell lung cancer. See the full release:http://investors.merrimack.com/node/11801
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This week we will be attending Baird's annual Global Health Conference. Tune in to the webcast on September 6 at 8:25 a.m.: https://bit.ly/2oJDf6r
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Innovation doesn't happen alone. Learn more about collaborating with us: http://bit.ly/2kHkgYd
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Innovation is at our core and we've built our culture on cooperation and collaboration. Learn more about our team and explore open career opportunities: http://bit.ly/2kFPOxs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A cornerstone of our development strategy is to establish efficacy through clinical studies in biomarker-enriched patient populations. Learn more about our ongoing studies:Ê http://bit.ly/2IZaRtn
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're developing a new generation of treatments for
#cancer through a focused pipeline of precise, targeted therapies. Discover more: http://bit.ly/2mc6MV4Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our team cares deeply about our mission and is driven by a desire to improve the lives of patients. http://bit.ly/2mc6MV4 pic.twitter.com/o2e0BofShF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Check out our paper in
@scisignal exploring a multi-scale computational model we developed that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate.http://bit.ly/2mGnThVHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our programs are backed by our systems biology expertise and a clear clinical rationale. Explore our published research and presentations: http://bit.ly/2mc6MV4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Merrimack proslijedio/la je Tweet
Computational modeling predicts how cancer cells respond to combinations of
#chemotherapy and#DNArepair inhibitors@MerrimackPharma@MITpic.twitter.com/wmw3M3kYWcHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Check out our
@scisignal paper published yesterday exploring a computational model that predicts the effects of combining chemotherapy with DNA repair inhibitors:http://bit.ly/2mGnThVHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our pipeline is shaped by a clear understanding of cancer pathways (systems biology). Learn more: http://bit.ly/2IZaRtn pic.twitter.com/ib7KOtPPu6
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.